Four weeks of liraglutide or exenatide treatment improved trabecular bone mass and architecture in ovariectomized mice, with GLP-1 receptors found on bone cells suggesting direct skeletal effects.
GLP-1R expressed on bone cellsGLP-1 receptors were found on osteoclasts, osteoblasts, osteocytes, and bone marrow cells — indicating GLP-1 RAs may directly affect bone metabolism
What the researchers found
Chronic administration of the GLP-1 receptor agonists liraglutide (0.3 mg/kg/day) and exenatide (10 μg/kg/day) for four weeks significantly improved trabecular bone mass, connectivity, and structural parameters in ovariectomized (OVX) mice — a standard model of postmenopausal osteoporosis. However, no effect was seen on cortical bone or bone formation in vivo.
Importantly, GLP-1 receptors were found to be expressed in bone marrow cells, osteoclasts, osteoblasts, and osteocytes, indicating that GLP-1 RAs may act directly on bone tissue. Exenatide increased serum calcitonin (which inhibits bone resorption) and decreased sclerostin (which inhibits bone formation), suggesting complex modulation of bone metabolism.
Why it matters
With millions of people now taking GLP-1 receptor agonists for diabetes and obesity, understanding their effects on bone is clinically important — especially since some other diabetes drugs (like thiazolidinediones) weaken bones. This study provides reassuring evidence that GLP-1 RAs may actually benefit bone health, and the discovery of GLP-1 receptors on bone cells opens a potential new therapeutic angle for osteoporosis.
How the study worked
Female mice were ovariectomized to induce postmenopausal bone loss. Four weeks later, they received daily injections of liraglutide (0.3 mg/kg), exenatide (10 μg/kg), or saline for four weeks. Bone micro-architecture was assessed by micro-CT, and bone formation/resorption were measured by histomorphometry with calcein and alizarin red labeling. Serum calcitonin and sclerostin were measured. GLP-1R expression was evaluated by RT-PCR and immunohistochemistry. In vitro assays tested GLP-1 RA effects on primary osteoclast and osteoblast cultures.
Who was studied
Ovariectomized female C57BL/6 mice (postmenopausal osteoporosis model)
What this study cannot tell us
This is a mouse study and results may not directly translate to humans. The treatment duration was only four weeks. GLP-1 RAs improved trabecular but not cortical bone, and in vitro effects on bone cells were complex (stimulating osteoclast differentiation while reducing resorption per cell). The doses used may not correspond to human therapeutic doses.
How to read the evidence
This is a preliminary-grade animal study using a well-established osteoporosis model (OVX mice). The combination of in vivo bone imaging, histomorphometry, serum markers, and in vitro cell studies provides robust mechanistic data, but human translation remains to be confirmed.
When this study was published
Published in 2015, this was an early study investigating GLP-1 RA effects on bone. Since then, epidemiological data from human GLP-1 RA users have begun to accumulate, generally supporting a neutral-to-beneficial bone profile.
The bigger picture
As GLP-1 receptor agonists become among the most prescribed drugs globally for diabetes and obesity, understanding their full-body effects is critical. This study adds bone health to the growing list of potential benefits, joining cardiovascular, renal, and hepatic protection. For postmenopausal women taking GLP-1 RAs, this could represent an important secondary benefit.
Questions still open
- Do GLP-1 receptor agonists reduce fracture risk in human patients taking them for diabetes or obesity?
- Why did GLP-1 RAs improve trabecular but not cortical bone — and does this pattern hold in human studies?
- Could GLP-1 RAs be developed as a treatment for osteoporosis independent of their metabolic effects?
Common questions
Could GLP-1 drugs like Ozempic help prevent osteoporosis?
Why is it important that bone cells have GLP-1 receptors?
Read the original research
Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.
Bone, 81, 459-467
Citation
Pereira, M; Jeyabalan, J; Jørgensen, C S; Hopkinson, M; Al-Jazzar, A; Roux, J P; Chavassieux, P; Orriss, I R; Cleasby, M E; Chenu, C. (2015). Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.. Bone, 81, 459-467. https://doi.org/10.1016/j.bone.2015.08.006